ArticleInternational journal of molecular sciences2023

A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.

Barbara-Ann Guinn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.